HPHayden M. Pagendarm

Hayden M. Pagendarm

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hayden M. Pagendarm has a total of 78 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Albumin-binding nanobody cancer vaccines coordinate lymphatic T cell priming and inflammatory remodeling of the tumor microenvironment

    by John Wilson, Hayden Pagendarm, Neil Chada, Taylor Patino, Alexander Kwiatkowski, Mia Woodruff, Jacob Schulman, Katherine Young, Christopher Lofts, Emmanuela Adjei-Sowah, et al.

    Cancer vaccines can generate tumor-specific T cells, but their efficacy against solid tumors is limited by an immunosuppressive tumor microenvironment (TME). To address this challenge, we developed nAlb-Vax, an albumin-binding nanobody vaccine platform designed to coordinate T cell priming in the lymphatic system with inflammatory remodeling of the TME. nAlb-Vax combines nanobody-fused peptide antigens with a nanobody-STING agonist conjugate as an adjuvant. Following subcutaneous (SC) administration, albumin binding enhanced antigen and adjuvant transport to draining lymph nodes (LNs), promoting antigen cross-presentation and antigen-presenting cell (APC) activation that elicited robust antigen-specific CD8+ T cell responses. nAlb-Vax subsequently entered systemic circulation and preferentially accumulated within tumors, promoting an immunostimulatory TME that enhanced infiltration, proliferation, and function of vaccine-induced T cells. Therapeutic vaccination inhibited tumor growth and extended survival across multiple established murine solid tumor models, outperforming conventional vaccine technologies and generating durable immunity against multiple tumor-specific antigens (TSAs). These findings demonstrate that exploiting physiological albumin trafficking can coordinate lymphatic T cell priming with inflammatory TME remodeling to improve therapeutic cancer vaccination.

  • Open Access

    A molecularly defined polymeric platform for environmentally responsive activation of STING to enhance cancer immunotherapy

    by Jacob A. Schulman, Karan Arora, Alexander J. Kwiatkowski, Neil C. Chada, Julia A. Steele, Hayden M. Pagendarm, Megan E. Woodworth, Taylor L. Sheehy, Katherine Gibson-Corley, Justin M. Balko, et al.


  • Open Access

    Nanoparticle Delivery of Alu RNA Adjuvants Enhances Vaccine Immunogenicity

    by Alexander J. Kwiatkowski, Jacob A. Schulman, Hayden M. Pagendarm, Lucinda E. Pastora, John T. Tossberg, Ruilin Zhang, Neil C. Chada, Mia E. Woodruff, Taylor L. Sheehy, Karan Arora, et al.

    Vaccine adjuvants stimulate innate immunity to enhance and shape adaptive immune responses. However, approved adjuvants typically elicit weak CD8+ T cell responses to protein- and peptide-based vaccines, motivating an investigation into the discovery and testing of new adjuvants. Unedited forms of endogenous Alu RNAs are sensed by pattern recognition receptors (PRRs) to trigger sterile inflammation, and therefore we hypothesized that synthetic Alu RNA molecules could be harnessed as vaccine adjuvants. To enhance their intracellular delivery, Alu RNA was copackaged with a model antigen into polymer nanoparticles that promoted endosomal escape of Alu RNA to the cytosol. Using this nanovaccine formulation, we found that Alu RNA activated antigen-presenting cells in vitro and in vaccine-site draining lymph nodes in vivo. Furthermore, we demonstrated that vaccine formulations containing Alu RNA as an adjuvant elicited comparable CD8+ T cell responses to those containing the common but highly heterogeneous RNA adjuvant PolyIC, and that this response protected mice from tumor challenge. Based on this, we further evaluated the antitumor efficacy of nanovaccine formulations containing Alu RNA adjuvants in mice with established tumors, again observing comparable responses to formulations containing PolyIC. Finally, we found that nanovaccines adjuvanted with Alu RNA could improve responses to anti-PD-1 immune checkpoint blockade in tumor-bearing mice. Overall, this study demonstrates that unedited Alu RNA coformulated with antigen in polymer nanoparticles can be harnessed as an effective vaccine adjuvant for stimulating CD8+ T cell responses with antitumor function and may offer a sequence-defined alternative to PolyIC.


  • Top Cited Papers
    Open Access

    Potentiating cancer immunotherapies with modular albumin-hitchhiking nanobody–STING agonist conjugates

    by Blaise R. Kimmel, Karan Arora, Neil C. Chada, Vijaya Bharti, Alexander J. Kwiatkowski, Jonah E. Finkelstein, Ann Hanna, Emily N. Arner, Taylor L. Sheehy, Lucinda E. Pastora, et al.

    The enhancement of antitumour immunity via agonists of the stimulator of interferon genes (STING) pathway is limited by pharmacological barriers. Here we show that the covalent conjugation of a STING agonist to anti-albumin nanobodies via site-selective bioconjugation chemistries prolongs the circulation of the agonist in the blood and increases its accumulation in tumour tissue, stimulating innate immune programmes that increased the infiltration of activated natural killer cells and T cells, which potently inhibited the growth of mouse tumours. The technology is modular, as demonstrated by the recombinant integration of a second nanobody domain targeting programmed death-ligand 1 (PD-L1), which further increased the accumulation of the agonist in tumours while blocking immunosuppressive PD-1/PD-L1 interactions. The bivalent nanobody–STING agonist conjugate stimulated robust antigen-specific T-cell responses and long-lasting immunological memory and conferred enhanced therapeutic efficacy. It was also effective as a neoadjuvant treatment to adoptive T-cell therapy. As a modular approach, hitchhiking STING agonists on serum albumin may serve as a broadly applicable strategy for augmenting the potency of systemically administered cancer immunotherapies.


  • Open Access

    Programable Albumin-Hitchhiking Nanobodies Enhance the Delivery of STING Agonists to Potentiate Cancer Immunotherapy

    by John Wilson, Blaise Kimmel, Karan Arora, Neil Chada, Vijaya Bharti, Alexander Kwiatkowski, Jonah Finklestein, Ann Hanna, Emily Arner, Taylor Sheehy, et al.

    Stimulator of interferon genes (STING) is a promising target for potentiating antitumor immunity, but multiple pharmacological barriers limit the clinical utility, efficacy, and/or safety of STING agonists. Here we describe a modular platform for systemic administration of STING agonists based on nanobodies engineered for in situ hitchhiking of agonist cargo on serum albumin. Using site-selective bioconjugation chemistries to produce molecularly defined products, we found that covalent conjugation of a STING agonist to anti-albumin nanobodies improved pharmacokinetics and increased cargo accumulation in tumor tissue, stimulating innate immune programs that increased the infiltration of activated natural killer cells and T cells, which potently inhibited tumor growth in multiple mouse tumor models. We also demonstrated the programmability of the platform through the recombinant integration of a second nanobody domain that targeted programmed cell death ligand-1 (PD-L1), which further increased cargo delivery to tumor sites while also blocking immunosuppressive PD-1/PD-L1 interactions. This bivalent nanobody carrier for covalently conjugated STING agonists stimulated robust antigen-specific T cell responses and long-lasting immunological memory, conferred enhanced therapeutic efficacy, and was effective as a neoadjuvant treatment for improving responses to adoptive T cell transfer therapy. Albumin-hitchhiking nanobodies thus offer an enabling, multimodal, and programmable platform for systemic delivery of STING agonists with potential to augment responses to multiple immunotherapeutic modalities.


  • Open Access

    Covalent Polymer‐RNA Conjugates for Potent Activation of the RIG‐I Pathway

    by Christian R. Palmer, Lucinda E. Pastora, Blaise R. Kimmel, Hayden M. Pagendarm, Alexander J. Kwiatkowski, Payton T. Stone, Karan Arora, Nora Francini, Olga Fedorova, Anna M. Pyle, et al.

    RNA ligands of retinoic acid‐inducible gene I (RIG‐I) are a promising class of oligonucleotide therapeutics with broad potential as antiviral agents, vaccine adjuvants, and cancer immunotherapies. However, their translation has been limited by major drug delivery barriers, including poor cellular uptake, nuclease degradation, and an inability to access the cytosol where RIG‐I is localized. Here this challenge is addressed by engineering nanoparticles that harness covalent conjugation of 5′‐triphospate RNA (3pRNA) to endosome‐destabilizing polymers. Compared to 3pRNA loaded into analogous nanoparticles via electrostatic interactions, it is found that covalent conjugation of 3pRNA improves loading efficiency, enhances immunostimulatory activity, protects against nuclease degradation, and improves serum stability. Additionally, it is found that 3pRNA could be conjugated via either a disulfide or thioether linkage, but that the latter is only permissible if conjugated distal to the 5′‐triphosphate group. Finally, administration of 3pRNA‐polymer conjugates to mice significantly increases type‐I interferon levels relative to analogous carriers that use electrostatic 3pRNA loading. Collectively, these studies have yielded a next‐generation polymeric carrier for in vivo delivery of 3pRNA, while also elucidating new chemical design principles for covalent conjugation of 3pRNA with potential to inform the further development of therapeutics and delivery technologies for pharmacological activation of RIG‐I.


  • Top Cited Papers
    Open Access

    A Cancer Nanovaccine for Co-Delivery of Peptide Neoantigens and Optimized Combinations of STING and TLR4 Agonists

    by Jessalyn J. Baljon, Alexander J. Kwiatkowski, Hayden M. Pagendarm, Payton T. Stone, Amrendra Kumar, Vijaya Bharti, Jacob A. Schulman, Kyle W. Becker, Eric W. Roth, Plamen P. Christov, et al.

    Immune checkpoint blockade (ICB) has revolutionized cancer treatment and led to complete and durable responses, but only for a minority of patients. Resistance to ICB can largely be attributed to insufficient number and/or function of antitumor CD8+ T cells in the tumor microenvironment. Neoantigen targeted cancer vaccines can activate and expand the antitumor T cell repertoire, but historically, clinical responses have been poor because immunity against peptide antigens is typically weak, resulting in insufficient activation of CD8+ cytotoxic T cells. Herein, we describe a nanoparticle vaccine platform that can overcome these barriers in several ways. First, the vaccine can be reproducibly formulated using a scalable confined impingement jet mixing method to coload a variety of physicochemically diverse peptide antigens and multiple vaccine adjuvants into pH-responsive, vesicular nanoparticles that are monodisperse and less than 100 nm in diameter. Using this approach, we encapsulated synergistically acting adjuvants, cGAMP and monophosphoryl lipid A (MPLA), into the nanocarrier to induce a robust and tailored innate immune response that increased peptide antigen immunogenicity. We found that incorporating both adjuvants into the nanovaccine synergistically enhanced expression of dendritic cell costimulatory markers, pro-inflammatory cytokine secretion, and peptide antigen cross-presentation. Additionally, the nanoparticle delivery increased lymph node accumulation and uptake of peptide antigen by dendritic cells in the draining lymph node. Consequently, nanoparticle codelivery of peptide antigen, cGAMP, and MPLA enhanced the antigen-specific CD8+ T cell response and delayed tumor growth in several mouse models. Finally, the nanoparticle platform improved the efficacy of ICB immunotherapy in a murine colon carcinoma model. This work establishes a versatile nanoparticle vaccine platform for codelivery of peptide neoantigens and synergistic adjuvants to enhance responses to cancer vaccines.


  • Open Access

    Engineering endosomolytic nanocarriers of diverse morphologies using confined impingement jet mixing

    by Hayden M. Pagendarm, Payton T. Stone, Blaise R. Kimmel, Jessalyn J. Baljon, Mina H. Aziz, Lucinda E. Pastora, Lauren Hubert, Eric W. Roth, Sultan Almunif, Evan A. Scott, et al.

    The clinical translation of many biomolecular therapeutics has been hindered by undesirable pharmacokinetic (PK) properties, inadequate membrane permeability, poor endosomal escape and cytosolic delivery, and/or susceptibility to degradation. Overcoming these challenges merits the development of nanoscale drug carriers (nanocarriers) to improve the delivery of therapeutic cargo. Herein, we implement a flash nanoprecipitation (FNP) approach to produce nanocarriers of diverse vesicular morphologies by using various molecular weight PEG-bl-DEAEMA-co-BMA (PEG-DB) polymers. We demonstrated that FNP can produce uniform (PDI < 0.1) particles after 5 impingements, and that by varying the copolymer hydrophilic mass fraction, FNP enables access to a diverse variety of nanoarchitectures including micelles, unilamellar vesicles (polymersomes), and multi-compartment vesicles (MCVs). We synthesized a library of 2 kDa PEG block copolymers, with DEAEMA-co-BMA second block molecular weights of 3, 6, 12, 15, 20, and 30 kDa. All formulations were both pH responsive, endosomolytic, and capable of loading and cytosolically delivering small negatively charged molecules – albeit to different degrees. Using a B16.F10 melanoma model, we showcased the therapeutic potential of a lead FNP formulated PEG-DB nanocarrier, encapsulating the cyclic dinucleotide (CDN) cGAMP to activate the stimulator of interferon genes (STING) pathway in a therapeutically relevant context. Collectively, these data demonstrate that an FNP process can be used to formulate pH-responsive nanocarriers of diverse morphologies using a PEG-DB polymer system. As FNP is an industrially scalable process, these data address the critical translational challenge of producing PEG-DB nanoparticles at scale. Furthermore, the diverse morphologies produced may specialize in the delivery of distinct biomolecular cargos for other therapeutic applications, implicating the therapeutic potential of this platform in an array of disease applications.


  • Open Access

    Flash nanoprecipitation for the production of endosomolytic polymersomes for cytosolic drug delivery

    by Hayden M Pagendarm, Payton T Stone, Jessalyn J Baljon, Mina H Aziz, Lucinda E Pastora, John T Wilson

    The delivery of biomacromolecular drugs to cytosolic targets has been a long-standing engineering challenge due to the presence of multiple biological barriers including cellular and endosomal membranes. Although many promising carriers designed to facilitate endosomal escape have been developed, the clinical translation of these carriers is often limited by complex production processes that are not amenable to scaled-up manufacturing. In this study, we employed flash nanoprecipitation (FNP) for the rapid, scalable, and reproducible assembly of nanocarriers composed of the pH-responsive, endosomolytic diblock copolymer poly[(ethylene glycol)x-block-[((2-diethylamino) ethyl methacrylate)0.6-co-(butyl methacrylate)0.4]y (PEG-b-DEAEMA-co-BMA). We found that varying the second block molecular weight, while holding the first block molecular weight constant, significantly influenced nanoparticle self-assembly and hence nanocarrier properties and function – including drug encapsulation, endosomolytic capacity, cytotoxicity, and in vitro activity of a cytosolically-active drug cargo, a cyclic dinucleotide (CDN) stimulator of interferon genes (STING) agonist. We found that while increasing second block molecular weight enhanced the capacity of nanocarriers to induce endosomal destabilization, larger second block molecular weights also lead to increased cytotoxicity, increased particle size and heterogeneity, increased the encapsulation efficiency of small (<0.5 kDa) hydrophilic drugs, decreased the encapsulation efficiency of large (10 kDa) hydrophilic biomacromolecules, and decreased long-term particle stability. Collectively, these results demonstrate the utility of FNP for the rapid and scalable production of uniform PEG-b-DEAEMA-co-BMA nanocarriers and implicate an optimal hydrophilic mass fraction for balancing desirable nanoparticle properties with cytosolic cargo delivery efficiency.